廣州白雲山医药集团股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(A joint stock company incorporated in the People's Republic of China with limited liability)

(於中華人民共和國註冊成立之股份有限公司)

(H share Stock Code H 股股份代碼: 00874)

12 May 2025

Dear registered shareholder(s),

Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited. (the "Company") is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"), which mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.gybys.com.cn, the company's third-party website at www.hmdatalink.com/C14070/tc/announcement.php and the HKEXnews website at www.hkexnews.hk in place of printed copies.

Solicitation of electronic contact details

To ensure timely receipt of the Actionable Corporate Communications^(Note), the Company recommends you provide your email address by scanning your personalized QR code printed on the enclosed reply form (the "**Reply Form**"). Alternatively, you may sign and return the Reply Form to the Company's Hong Kong share registrar (the "**H Share Registrar**"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the H Share Registrar, the Company will send the Actionable Corporate Communications (Note) in printed form in the future.

If you want to receive future Corporate Communications in printed form, please complete and return the Reply Form on the reverse side to the H Share Registrar or send an email to Baiyunshan.ecom@computershare.com.hk specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to this letter, please contact the H Share Registrar at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

The Board of

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited .

Note: Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

各位登記股東:

以電子方式發布公司通訊之安排

根據自 2023 年 12 月 31 日起生效的擴大無紙化上市機制及以電子方式發布公司通訊規定下香港聯合交易所有限公司證券上市規則(「**上市規則**」)第 2.07A條,廣州白雲山醫藥集團股份有限公司(「**公司**」)謹此通知 閣下,公司已採用以電子方式發布公司通訊(「**公司通訊**」)之安排,該公司通訊是指公司為向其任何證券持有人提供信息或提醒其採取行動而發布或將要發布的任何文件,包括但不限於(a)董事報告、年度帳目以及審計報告副本以及(如適用)財務摘要報告; (b)中期報告及其中期報告摘要(如適用); (c)會議通知; (d)上市文件; (e)通函和 (f)委任表格。

請注意,所有未來公司通訊的英文版和中文版將在公司網站 <u>www.gybys.com.cn</u>,公司第三方網站 <u>www.hmdatalink.com/C14070/tc/announcement.php</u> 和披露易網站 <u>www.hkexnews.hk</u> 上提供,以代替印刷本。

徵集電子聯絡資料

為確保及時收到可供採取行動的公司通訊^(標金),公司建議 閣下透過掃描本函背頁之回條(「**回條**」)上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。或者, 閣下也可以簽署回條並交回公司的香港股份過戶登記處(「**H 股股份登記處**」)香港中央證券登記有限公司,地址為香港灣仔皇后大道東183號合和中心17M 樓。

如果公司沒有收到 閣下的有效電子郵件地址,直至 H 股股份登記處收到 閣下有效的電子郵件地址前,本公司未來將以印刷本形式發送可供採取行動的公司通訊 $^{(Rit)}$ 。

若 閣下希望收取日後公司通訊之印刷本,請填妥本函背頁之回條並交回 H 股股份登記處,或發送電子郵件至 <u>Baiyunshan.ecom@computershare.com.hk</u>,並 註明 閣下的姓名、地址以及收取公司通訊印刷本的要求。請注意,收取日後公司通訊印刷本之指示由收悉 閣下指示當日起計一年內有效,此後將過期。

如 閣下對本函件有任何疑問,請於辦公時間星期一至五(香港公眾假期除外)上午9時正至下午6時正(香港時間)期間致電H股股份登記處(852)28628688 查詢。

廣州白雲山醫藥集團股份有限公司 董事會

2025年5月12日

附註:可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊。

REPLY FORM 回條			
To: Computershare Hong Kong Investor Services (The "H Share Registrar") 17M Floor, Hopewell Centre 183 Queen's Road East, Wanchai, Hong Kong		香港中央證券登記有限公司 (「H 股股份登記處」) 香港灣仔皇后大道東 183 號 合和中心 17M 樓	
(Please <u>choose ONLY ONE</u> of the options below) (請 <u>從以下選項中只選擇其中一項)</u>			
Option 1: Provide your email address for receipt of future Actionable Corporate Personalized QR Code Communications ^(Note 3) of the Company via electronic dissemination by scanning your personalized QR code 選項1: 掃瞄 閣下專屬二維碼提供 閣下之電子郵件地址・以接收公司未來通過電子方式 發佈可供採取行動的公司通訊(問註3)			
You are NOT required to return this Reply Form if you choose Option 1. 如選擇了選項 1. 閣下 無須 交回本回條。			
Option 2: I/we hereby provide my/our email address in writing for receipt of future Actionable Corporate Communications (Note 3) of the following listed company (the "Company") via electronic dissemination 選項2: 本人/吾等現以書面提供本人/吾等之的電子郵件地址・以確保收到以下上市公司(「公司」)未來通過電子方式發佈可供採取行動的公司通訊 (開註3)			
Name of Securities holder(s) 證券持有人姓名:	Name of the listed comp		
	Guangzhou Baiyunsha	n Pharmaceutical Holdings Company Limited	
Email address 電郵地址: (Notes 3 / 附註3)			
Option 3: I/we hereby request for receipt of Cor	navata Communications*in maintal form (I	blacco monty "-(") in the helevy hery if anniceable)	
Option 3: I/we hereby request for receipt of Corporate Communications*in printed form (Please mark "✓" in the below box if applicable) 選項 3: 本人/吾等現要求收取公司通訊*印刷版 (如適用・請在以下方格內劃上「✓」號)			
receive future Corporate Communications* in printed copy and noted that this instruction is valid only for one year starting from the receipt date of instruction until the			
instruction has been revoked, superseded or expired	d. (Notes 5)	(W苯氧	
收取未來公司通訊"的印刷本,並已知悉本指示	_		
	17717171	ed English and Chinese versions 中、英文印刷本	
Signature(s): ^(Notes 1) 簽名: ^(附註 1)	Contact number: 聯絡電話號碼:	Date: 日期:	

- otes 附註:
 Please complete all your details clearly. If your shares are held in joint names, all of the joint shareholders should jointly sign this Reply Form in order to be valid.
 請清楚填妥 圖下之所有資料。如圖夢名殷東 則本回餘須由所有鄭名殷東聯合簽書。方為有效。
 Any Reply Form with no signature or otherwise incorrectly completed will be void.
 任何回錄若未有養書或在其他方面填寫不正確。則本回錄將首首作撥。
 If the Company does not receive a functional email address in your reply, the Company will send the Actionable Corporate Communication in printed form in the future. Actionable Corporate Communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.
 如公司沒有政制 圖下的有效電子郵件地址、本公司將以即剩本形式發送可供採取行動的未來公司通訊。可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示具戴如何行使具有關證券持有人的權利的公司通訊。
- アンスニー If you provide more than one email address by QR code, email, reply form and/or other means, only the latest one email address provided will be registered. 如 閣下通過二維碼、電郵、回條及/或其他方式提供多於一個的電子郵件地址・只有 閣下最後提供的電子郵件地址將會被用於登記・
- If you mark "✔" in the box in Option 3, no email address will be registered and only Corporate Communications* in printed form will be received. 如 間下在選項 3 方格内劃上「✔」號,將不會有電子郵件地址被登記,只有公司通訊*的印刷版會被收取。

- report, interim report, notice of meeting, circular and proxy form. 除非另有註明·公司通訊乃指公司已發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件·其中包括但不限於年報、中期報告、會議通告、通函及代表委任表格。

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明

- SONAL INFORMATION COLLECTION STATEMENT 個人資料單。 "Personal Data" in the Personal Data "in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO").
 本管明中所指的「個人資料」與香港法例第 486章 《個人資料(私隱)條例》(「《私隱條例》」)中「個人資料」的涵義相同。
 Your Personal Data provided in this Reply Form will be used in connection with, including but not limited to, the Company's electronic dissemination of Corporate Communications and to liaise with you on other matters relating to your holdings in the Company, Your supply of Personal Data to the Company's location and/or request as stated in this Reply Form.
 图下於本□極條所提供的個人資料無用於(包括但不限於)有關公司以電子方式發布公司適訊及就 關下持有的公司證券有關的其他事宜上與 關下聯絡。關下是自願向本公司提供個人資料。若關下未能提供足夠資料、本公司可能無法處理 關下在本回條上所述的指示及/或要求。
 Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the H Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes.
 公司可就任何所說明的用途或在法例規定的情况下,將 關下的個人資料披露或轉移給公司的附屬公司,H 股股份登記處、及/或其他公司或團體。並將在適當期間保留該等個人資料作核實及紀錄用途,You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Orivacy Officer of the H Share Registrar at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong or by email at PrivacyOfficer computershare, com.ht.

 图下有程度模式 化原格的,的核文量的及或修改 图下的個人資料,任何該等量関及/或修改图人更快的更大的。我们就是可以可以使用的一个可以使用 (ii)
- (iii)

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited 香港中央證券登記有限公司 Freepost No. 簡便回郵號碼: 37 Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this form to us.

No postage is necessary if posted in Hong Kong.

閣下寄回此回條時・請將郵寄標籤剪貼於信封上 如在本港投寄・ 閣下無需支付郵費或貼上郵票。